Both these authors contributed equally to this study.
P2Y1 receptors mediate inhibitory neuromuscular transmission in the rat colon
Article first published online: 28 OCT 2009
© 2009 The Authors. Journal compilation © 2009 The British Pharmacological Society
British Journal of Pharmacology
Volume 158, Issue 6, pages 1641–1652, November 2009
How to Cite
Grasa, L., Gil, V., Gallego, D., Martín, M. T. and Jiménez, M. (2009), P2Y1 receptors mediate inhibitory neuromuscular transmission in the rat colon. British Journal of Pharmacology, 158: 1641–1652. doi: 10.1111/j.1476-5381.2009.00454.x
- Issue published online: 28 OCT 2009
- Article first published online: 28 OCT 2009
- Received 30 March 2009; revised 23 June 2009; accepted 7 July 2009
- smooth muscle;
- inhibitory neuromuscular transmission;
- P2Y1 receptors;
- nitric oxide;
Background and purpose: Inhibitory junction potentials (IJP) are responsible for smooth muscle relaxation in the gastrointestinal tract. The aim of this study was to pharmacologically characterize the neurotransmitters [nitric oxide (NO) and adenosine triphosphate (ATP)] and receptors involved at the inhibitory neuromuscular junctions in the rat colon using newly available P2Y1 antagonists.
Experimental approach: Organ bath and microelectrode recordings were used to evaluate the effect of drugs on spontaneous mechanical activity and resting membrane potential. IJP and mechanical relaxation were studied using electrical field stimulation (EFS).
Key results: Nω-nitro-L-arginine (L-NNA) inhibited the slow component of the IJP and partially inhibited the mechanical relaxation induced by EFS. MRS2179, MRS2500 and MRS2279, all selective P2Y1 receptor antagonists, inhibited the fast component of the IJP without having a major effect on the relaxation induced by EFS. The combination of both L-NNA and P2Y1 antagonists inhibited the fast and the slow components of the IJP and completely blocked the mechanical relaxation induced by EFS. Sodium nitroprusside caused smooth muscle hyperpolarization and cessation of spontaneous motility that was prevented by oxadiazolo[4,3-α]quinoxalin-1-one. Adenosine 5′-O-2-thiodiphosphate, a preferential P2Y agonist, hyperpolarized smooth muscle cells and decreased spontaneous motility. This effect was inhibited by P2Y1 antagonists.
Conclusions and implications: The co-transmission process in the rat colon involves ATP and NO. P2Y1 receptors mediate the fast IJP and NO the slow IJP. The rank order of potency of the P2Y1 receptor antagonists is MRS2500 greater than MRS2279 greater than MRS2179. P2Y1 receptors might be potential pharmacological targets for the regulation of gastrointestinal motility.
area under the curve
electrical field stimulation
inhibitory junction potential
fast component of the IJP
slow component of the IJP
Stimulation of inhibitory motor neurones by electrical field stimulation (EFS) causes the release of inhibitory neurotransmitter(s). Smooth muscle responds with a transient inhibitory junction potential (IJP), which is the electrophysiological base of smooth muscle relaxation. IJP usually display two components: a fast (IJPf) followed by a slow (IJPs) component. These two components suggest the release of at least two inhibitory neurotransmitters (Crist et al., 1992; Lyster et al., 1992; He and Goyal, 1993; Keef et al., 1993; Pluja et al., 1999; Gallego et al., 2006). Experiments with new pharmacological tools are essential to characterize the co-transmission process where nitric oxide (NO) and ATP might be involved (Burnstock, 2008; Gallego et al., 2008a). It has been clearly demonstrated that the IJPs is abolished by treatments that block NO synthesis (Keef et al., 1993; Pluja et al., 1999; Wang et al., 2007); this indicates that the IJPs is mediated by NO release from inhibitory motor neurones. In contrast, NO synthase inhibition does not alter the IJPf, showing that this component is not mediated by NO.
ATP, or a related purine, is an inhibitory neurotransmitter in the gut (Burnstock et al., 1970; Ralevic and Burnstock, 1998). There are two families of purine receptors: P2X and P2Y. P2X receptors are ligand-gated ion channels, and P2Y receptors are G-protein coupled receptors. Eight distinct P2Y receptor subtypes, P2Y1,2,4,6,11,12,13,14 and seven P2X receptor subtypes, P2X1–7, have been reported (Burnstock, 2007).
MRS2179 is a selective antagonist of P2Y1 receptors that has been recently used to characterize purinergic inhibitory neurotransmission in the gastrointestinal (GI) tract (Boyer et al., 1998; Camaioni et al., 1998; Alexander et al., 2008). However, findings are not conclusive, and the effect of MRS2179 might vary between species and areas of the GI tract. In the human colon (Gallego et al., 2006; 2008a), guinea pig ileum (Wang et al., 2007) and pig small intestine (Gallego et al., 2008b), the IJPf is sensitive to MRS2179. In rodents, the non-nitrergic relaxation is partially sensitive to MRS2179; the response of circular muscle strips of mouse jejunum are affected by MRS2179 at a concentration of 1 µM (De Man et al., 2003). Moreover, adenosine 5′-O-2-thiodiphosphate (ADPßS), a preferential P2Y agonist, induces MRS2179-sensitive relaxations in the rat distal colon. It has thus been postulated that post-junctional P2Y1 receptors located in smooth muscle mediate the non-nitrergic relaxation in murine tissues (Giaroni et al., 2002; Van Crombruggen et al., 2007). Higher concentrations of MRS2179 (10 µM) are needed to inhibit the IJPf in the mouse internal anal sphincter (McDonnell et al., 2008) and caecum (Zizzo et al., 2007). These results suggest that other P2Y receptors might be involved in inhibitory neurotransmission (McDonnell et al., 2008), or, alternatively, pre-junctional P2Y1 receptors might mediate this effect (Zizzo et al., 2007).
Specific P2Y receptor antagonists are essential pharmacological tools for the proper characterization of purinergic inhibitory neurotransmission (Bornstein, 2008). In this study, we investigated inhibitory neurotransmission in the rat mid-colon using MRS2179 (Camaioni et al., 1998), and, for the first time, two other recently available P2Y1 antagonists, MRS2279 (Boyer et al., 2002) and MRS2500 (Kim et al., 2001); (Cattaneo et al., 2004). Briefly, we found that the IJPf and the non-nitrergic relaxation evoked by EFS were inhibited in a concentration-dependent manner by MRS2179, MRS2500 and MRS2279, indicating the involvement of P2Y1 receptors in the purinergic inhibitory neurotransmission in the rat mid-colon. Further study of these P2Y1 receptors is crucial to establish them as pharmacological targets in the regulation of gastrointestinal functions, such as secretion and motility (Wood, 2006).
Male Sprague-Dawley rats (300–350 g), 8–10 weeks old, were kept at a constant temperature (19–21°C) and humidity (60%), with a lighting cycle of 12 h light/12 h dark and had access to water and food ad libitum. The rats were killed by stunning, a sharp blow to the head, before being decapitated and bled. This procedure was approved by the Ethics Committee of the Universitat Autònoma de Barcelona.
The mid-colon was quickly removed and placed in carbogenated Krebs solution. The mesenteric fat was removed, and the colon was opened along the mesenteric border and pinned to a Sylgard base with the mucosa facing upward. The mid-colon was distinguished according to the longitudinal orientation of the folds of the mucosa (total length about 5 cm in the centre of the colon) according to anatomical criteria previously described (Alberti et al., 2005). Mucosal and submucosal layers were carefully removed, and the circular muscle was cut into strips 1 cm long and 0.3 cm wide.
Intracellular microelectrode recording
Muscle strips were pinned to the base of a Sylgard-coated chamber, circular muscle side up, and continuously perfused with Krebs solution. Strips were allowed to equilibrate for approximately 1 h before the recording commenced. Circular smooth muscle cells were impaled with glass microelectrodes filled with 3 M KCl (30–60 MΩ of resistance). Membrane potential was measured using standard electrometer Duo773 (WPI Inc., Sarasota, FL, USA). Tracings were displayed on an oscilloscope 4026 (Racal-Dana Ltd., Windsor, UK) and simultaneously digitalized (100 Hz) using PowerLab 4/30 system and Chart 5 software for Windows (all from ADInstruments, Castle Hill, NSW, Australia). EFS was applied using two silver chloride plates placed perpendicular to the longitudinal axis of the preparation and 1.5 cm apart. The EFS had the following parameters: total duration of train, 100 ms; frequency, 20 Hz; pulse duration, 0.3 ms, and increasing amplitude voltage, 5, 10, 12, 15, 17, 20, 25, 30 and 50 V. The amplitude and the duration of the EFS-induced IJP were measured under control conditions and after infusion of each drug. Resting membrane potential was also measured before and after drug addition. Nifedipine (1 µM) was used to abolish the mechanical activity and obtain stable impalements.
Spontaneous mechanical activity was studied in a 10 mL organ bath. Circularly orientated preparations were tied to a support at one end and to an isometric force transducer (Harvard VF-1, Harvard Apparatus Inc., Holliston, MA, USA) at the other using a 2/0 silk thread. Mechanical activity was recorded by means of the transducer, which was connected to a personal computer through an amplifier. Data were digitalized (25 Hz) using Data 2001 software (Panlab, Barcelona, Spain) coupled to an A/D converter. A tension of 1 g was applied, and the tissue was allowed to equilibrate for 1 h. After this period, strips displayed spontaneous phasic activity. In order to study the inhibitory neurotransmitters released, EFS was applied for 4 min (pulse duration, 0.3 ms; frequency, 5 Hz; amplitude, 30 V) through two platinum electrodes placed on the support holding the tissue. To estimate mechanical activity responses to drugs or EFS, the area under the curve (AUC) of contractions from the baseline was measured before and after drug addition and before and during EFS. AUC is expressed as g·min−1.
Solutions and drugs
The composition of the Krebs solution was (in mM): glucose, 10.10; NaCl, 115.48; NaHCO3, 21.90; KCl, 4.61; NaH2PO4, 1.14; CaCl2, 2.50 and MgSO4, 1.16 (pH 7.3–7.4). The Krebs solution (37 ± 1°C) was bubbled with carbogen (95% O2 and 5% CO2). In all the experiments, phentolamine, atropine and propanolol 1 µM was added to the Krebs solution to block α- and β-adrenoceptors and muscarinic receptors.
The following drugs were used: nifedipine, Nω-nitro-L-arginine (L-NNA), ADPβS, phentolamine, sodium nitroprusside (SNP) 1H-[1,2,4], oxadiazolo[4,3-α]quinoxalin-1-one (ODQ) (Sigma Chemicals, St. Louis, MO, USA), atropine sulphate (Merck, Darmstadt, Germany), propanolol, 2′-deoxy-N6-methyladenosine 3′,5′-bisphosphate tetrasodium salt (MRS2179), (1R,2S,4S,5S)-4-[2-chloro-6-(methylamino)-9H-purin-9-yl]-2-(phosphonooxy)bicyclo[3.1.0]hexane-1-methanol dihydrogen phosphate ester diammonium salt (MRS2279), and (1R,2S,4S,5S)-4-[2-Iodo-6-(methylamino)-9H-purin-9-yl]-2-(phosphonooxy)bicyclo[3.1.0]hexane-1-methanol dihydrogen phosphate ester diammonium salt (MRS2500) (Tocris, Bristol, UK). Stock solutions were made by dissolving drugs in distilled water, except for nifedipine and ODQ, which were dissolved in 96% ethanol and L-NNA, which was dissolved in Krebs solution by sonication. Drug and receptor nomenclature conform to the guidelines of the British Journal of Pharmacology (Alexander et al., 2008)
Data analysis and statistics
Differences in the resting membrane potential before and after infusion of different drugs were compared by one-way analysis of variance (anova) followed by Bonferroni post hoc test. The duration of the IJP was measured from the beginning of the hyperpolarization to the value of a stable resting membrane potential. The differences between the amplitude and duration of the IJPs before and after drug infusion were compared by two-way anova (drug and voltage).
To normalize mechanical data, the effect of drugs and EFS were calculated as percentage of inhibition, being 100% when a total inhibition of spontaneous motility was recorded after drug administration or during EFS, and 0% when the inhibitory response was completely antagonized. Rebound contraction recorded at the end of the timulus was normalized with the average amplitude of spontaneous contractions before EFS. One-way anova was used (i) to evaluate the effect of drugs on inhibition of spontaneous motility induced by SNP or ADPßS; and (ii) to evaluate the effect of different antagonists on inhibition of spontaneous motility and rebound contraction evoked by EFS. Paired t-test was used to compare data when two single groups were studied.
Data are expressed as mean ± SEM. P < 0.05 was considered statistically significant; n values indicate the number of samples. Statistical analysis was performed with GraphPad Prism version 4.00 (GraphPad Software, San Diego, CA, USA).
Role of nitric oxide synthase inhibitors in the IJP and relaxation induced by EFS
EFS completely inhibited spontaneous motility, and a rebound contraction (off-contraction) was recorded after the end of the stimulus. The amplitude of the off-contraction was 1.51 ± 0.11 (n= 18) higher than the mean spontaneous contraction. L-NNA (1 mM, n= 11) partially decreased the inhibitory effect induced by EFS by about 23 ± 6% (Figure 1A). However, L-NNA (1 mM, n= 11) did not significantly modify the rebound contraction [control: 1.66 ± 0.14 vs. L-NNA: 1.60 ± 0.07; t-test not significant (n.s.)]. As previously reported, EFS caused an IJP with two components: an IJPf (measured as the IJP amplitude) followed by an IJPs (measured as the IJP duration at baseline) (Pluja et al., 1999; control tracings of Figures 2 and 4). Both the amplitude and duration of the IJP were voltage dependent. Neither L-NNA (1 mM, n= 4) nor the guanylate cyclase inhibitor ODQ (10 µM, n= 8) modified the amplitude of the IJP, but they did reduce its duration (anovaP < 0.0001), that is 50 V: control: 3.4 ± 0.4 s versus L-NNA: 2.3 ± 0.2 s and control: 3.7 ± 0.3 s versus ODQ: 2.7 ± 0.3 s. The remaining IJP was the IJPf that is sensitive to P2Y1 antagonists (see below).
Role of P2Y1 antagonists in the IJP and relaxation induced by EFS
Muscle bath experiments demonstrated that MRS2179 (10 µM, n= 7 and 20 µM, n= 5), MRS2279 (1 µM, n= 5) and MRS2500 (1 µM, n= 5) did not modify the inhibitory effect induced by EFS (Figure 1B–D). The amplitude of the rebound contraction was not modified by the different P2Y1 antagonists tested (paired t-test): that is control: 1.27 ± 0.17 versus MRS2179 (10 µM) 1.40 ± 0.25, (n= 7, n.s), control: 1.47 ± 0.30 versus MRS2179 (20 µM) 1.48 ± 0.32, (n= 5, n.s), control: 1.28 ± 0.20 versus MRS2279 (1 µM) 0.83 ± 0.23, (n= 5, n.s), and control: 1.35 ± 0.09 versus MRS2500 (1 µM) 0.88 ± 0.16, (n= 5, n.s.). The amplitude of rebound contraction was normalized in relation to spontaneous motility (see Methods). The electrophysiological experiments demonstrated that MRS2179 (20 µM; n= 6), MRS2279 (1 µM; n= 4) and MRS2500 (1 µM; n= 8) did not modify the duration but did markedly reduce the amplitude of the IJP (Figure 2). It is important to note that the inhibitory effect was more prominent in experiments performed with MRS2279 (1 µM) and MRS2500 (1 µM) than in those performed with MRS2179 (20 µM). In experiments with MRS2179, the IJPf was recovered after 20 min washout, but in experiments with MRS2279 and MRS2500, the IJPf was only partially recovered after washout.
Role of NOS inhibitors and P2Y1 antagonists in the IJP and relaxation induced by EFS
In order to characterize the neurotransmission process, preparations were first incubated with L-NNA (1 mM), and then the effects of the P2Y1 antagonists were studied. Muscle bath experiments show a concentration-dependent inhibition of EFS-induced relaxation (Figure 3). IC50 values were: MRS2179, 3.5 µM; MRS2279, 43.9 nM; MRS2500, 16.5 nM. Note, in the presence of high concentrations of the P2Y1 antagonists, an initial contraction is seen at the onset of the stimulus, contrasting with the relaxation seen in control (Figure 3). In the presence of L-NNA, the rebound contraction was reduced in a concentration-dependent manner by the P2Y1 receptor antagonists. MRS2279 and MRS2500 caused a total inhibition of rebound contraction at 1 µM (Bonferroni's multiple comparison test, control vs. 1 µM, P < 0.001 both). In the presence of both L-NNA and the P2Y1 antagonists, a reduction of both the amplitude and the duration of the IJPs was observed (Figure 4). Concentration-response curves were performed in the presence of L-NNA (Figure 5). IC50 values were: MRS2179, 13.1 µM; MRS2279, 17.8 nM; MRS2500, 14.0 nM. Both 1 µM MRS2279 and 1 µM MRS2500 completely blocked the IJP. In contrast, a residual IJP was still recorded with 20 µM MRS2179.
Effect of NO donors on membrane potential and spontaneous motility
Incubation of the tissue with SNP (1 µM), an NO donor, caused a smooth muscle hyperpolarization (−11 ± 0.7 mV; n= 18) and a long-lasting (more than 10 min) cessation of spontaneous motility (AUC 11.40 ± 1.94 vs. 0.07 ± 0.05 g·min−1; n= 4 t-test P < 0.01) (Figure 6 A,B respectively). The hyperpolarization induced by SNP 1 µM was not modified by pre-incubation with either L-NNA, MRS2500 or MRS2279 (Figure 6A). ODQ (10 µM) partially antagonized the hyperpolarization induced by SNP (Figure 6A). The inhibition of spontaneous motility induced by SNP (1 µM) was also not modified by either L-NNA, MRS2179, MRS2279 or MRS2500 (Figure 6B). In the presence of these antagonists, SNP (1 µM) caused a total inhibition (100%) of spontaneous motility. SNP caused only a partial inhibition of spontaneous motility (8.4 ± 2.2%; P < 0.001) in the presence of ODQ (10 µM) (Figure 6B).
Effect of ADPβS on membrane potential and spontaneous motility
Incubation of the tissue with ADPβS (10 µM) caused a transient (5 min) inhibition of spontaneous motility (AUC: 9.01 ± 1.47 vs. 4.04 ± 0.76 g·min−1; n= 14, t-test P < 0.001) (Figure 7). This inhibitory effect was reversed by MRS2179, MRS2279 and MRS2500, but not by ODQ or L-NNA (Figure 7B). ADPßS (10 µM) induced a hyperpolarization of 9.15 ± 0.71 mV (n= 25), which was antagonized by MRS2179, MRS2279 and MRS2500 but not modified by pre-incubation with either L-NNA or ODQ (Figure 7A)
In the present study, we have demonstrated that in the rat colon, the fast component of the IJP is sensitive to P2Y1 antagonists, and the slow component to NOS inhibitors. A combination of NOS inhibitors and P2Y1 antagonists completely blocked the inhibition of spontaneous motility induced by EFS and the off-contraction observed at the end of the stimulus. These results suggest that ATP (or a related purine) and NO are two neurotransmitters that act through P2Y1 receptors and the cGMP pathway respectively. The selective P2Y1 receptor antagonists tested in the present study showed different potency, MRS2500 being greater than MRS2279, which was greater than MRS2179.
The present experiments are a continuation of a previously published study where we demonstrated that the IJPf in the rat colon is mainly sensitive to apamin and suramine, and the IJPs is sensitive to NOS inhibitors (Pluja et al., 1999). Suramine is a non-selective purinergic antagonist, and in the present study, we have used newly available pharmacological tools to characterize the co-transmission process.
MRS2179 was the first P2Y1 selective receptor antagonist to be characterized (Camaioni et al., 1998). This antagonist has been used in several biological systems involving P2Y1 receptors, such as an inhibitor of platelet aggregation (Baurand et al., 2001; Baurand and Gachet, 2003) or nucleotide-mediated relaxation in guinea pig aorta (Kaiser and Buxton, 2002). Recently, two other P2Y1 antagonists, MRS2279 and MRS2500, have become available, and they show comparatively higher affinity and potency to the P2Y1 receptor (Kim et al., 2001; Boyer et al., 2002; Cattaneo et al., 2004). All these compounds are essential pharmacological tools for investigating functions involving P2Y1 receptors (King, 2002). This is the first study in which the selective P2Y1 antagonists MRS2279 and MRS2500 have been used to investigate the IJP and non-nitrergic relaxation in the GI tract. Our results show that all the antagonists were able to inhibit the IJPf, the non-nitrergic relaxation and the off-contraction induced by EFS, though with varying potency. MRS2279 and MRS2500 blocked the IJP in the micromolar range, but higher concentrations (up to 20 µM) of MRS2179 were needed to partially inhibit the IJP. Consistent with this result, P2Y1 antagonists had a different range of potency in the non-nitrergic relaxation induced by EFS, MRS2500 being greater than MRS2279, which was greater than MRS2179. The rank order of antagonist potency is similar to that described in the literature (Cattaneo et al., 2004; Von Kugelgen, 2006). The effect of MRS2179 is completely washable, but the effect of MRS2279 and MRS2500 is only partially washable, and this might be due to varying sensitivity to ectonucleases (Ravi et al., 2002). Accordingly, MRS2500 has been used as a stable antithrombotic agent in vivo (Hechler et al., 2006).
Differences between species might explain present and previously published data. According to the present results and those from other studies (Zizzo et al., 2007; McDonnell et al., 2008), the inhibitory effect of MRS2179 is less potent in rodents than in humans (Gallego et al., 2008a), pigs (Gallego et al., 2008b) or guinea pigs (Wang et al., 2007). In human colon and pig small intestine, the IC50 of MRS2179 is close to 1 µM, but in rats, a higher concentration is needed to inhibit EFS-induced relaxation and off-contraction. MRS2279 and MRS2500 have not been used in human colon, but preliminary data from our laboratory show that this antagonist inhibits the human IJPf and relaxation in the nM range. All these data are consistent with a major role of post-junctional P2Y1 receptors in mediating IJPf and non-nitrergic relaxation. The presence of other P2Y receptors in the internal anal sphincter of mice (McDonnell et al., 2008), or, alternatively, a pre-junctional effect of P2Y receptors in the mouse caecum, has been recently postulated (Zizzo et al., 2007). According to the data presented in the present work, further research is needed with more potent P2Y1 antagonists to determine whether the maximal effect has been reached in these tissues. In the rat colon, only P2Y1 and P2Y6 receptors have been immunolocalized in smooth muscle cells (Van Crombruggen et al., 2007). However, MRS antagonists fail to block the rat P2Y6 receptors expressed in human astrocytoma cells (Boyer et al., 1998). P2Y1 receptors are located in enteric neurones in several species (Gao et al., 2006; Gallego et al., 2008b) and mediate slow excitatory postsynaptic potentials in neurones from the guinea-pig submucous plexus (Hu et al., 2003; Monro et al., 2004) and myenteric plexus (Gwynne and Bornstein, 2009). A pre-junctional effect of P2Y1 receptors inhibiting ATP release is possible, but P2Y1 receptors have not been detected in enteric neurones in the rat colon (Van Crombruggen et al., 2007). In a fine, recent study, P2Y1 and P2Y11 receptors were shown to mediate the fast and slow relaxation, respectively, in the guinea-pig taenia coli (King and Townsend-Nicholson, 2008). In the guinea pig taenia coli, both P2Y1 and P2Y11 receptors are present in smooth muscle cells and α-β meATP activated P2Y11 receptors, causing smooth muscle relaxation. However, MRS2179 did not antagonize calcium increase induced by purinergic activation of human P2Y11 receptors transfected in a human astrocytoma cell line (King and Townsend-Nicholson, 2008). In the rat colon, neither have P2Y11 receptors been detected in smooth muscle cells, nor in interstitial cells of Cajal, which might participate in neurotransmission (Van Crombruggen et al., 2007). All these data are consistent with a major role of P2Y1 receptors in the generation of IJPf and non-nitrergic relaxation. However, the possibility that other extrajunctional P2Y receptors are involved in smooth muscle relaxation needs further research.
It is important to note that blockade of P2Y1 receptors alone does not modify the duration of the IJP nor the inhibition induced by EFS. According to our results, the ‘non-purinergic’ relaxation is mainly nitrergic. This is consistent with recently published data on the human colon where P2Y1 antagonist inhibited IJPf but not the sustained IJP elicited by electrical pulses (Gallego et al., 2008a). In the presence of purinergic blockade, the nitrergic IJP causes smooth muscle hyperpolarization, the membrane potential does not reach the threshold to open calcium channels, and, consequently, spontaneous contractions do not occur. At the end of the stimulus, smooth muscle repolarization probably activates L-type calcium channels, and an off-contraction occurs. In agreement with these results, SNP, an NO donor, causes long-lasting hyperpolarization and smooth muscle relaxation (Pluja et al., 1999), which are sensitive to ODQ, but not to P2Y1 receptor antagonists (present work).
In contrast, NO synthase inhibition reduced the IJPs but not IJPf; a partial effect on the inhibition of spontaneous motility was observed in the presence of L-NNA. In this case, the ‘non-nitergic’ IJP is mainly purinergic through P2Y1 receptors. It is possible that the reduction in the IJP duration would result in smooth muscle cells transiently reaching the threshold to open calcium channels, and this could explain the partial contractions present during EFS. A similar result has been reported in the human colon (Gallego et al., 2008a).
In conclusion, the present work demonstrates that in the rat colon, a co-transmission process that involves ATP through P2Y1 receptors, and NO is present. As described in other species, P2Y1 receptors are responsible for the IJPf, and NO is responsible for the IJPs. The rank order of potency for the P2Y1 receptor antagonists in the rat colon is MRS2500 greater than MRS2279, which is greater than MRS2179. It would be interesting to investigate the potencies of these antagonists in human colonic tissue.
The authors thank Claudia Arenas and Emma Martínez for their technical assistance. Víctor Gil is supported by the Ministerio de Ciencia e Innovación (AP2007–01583). This work has been funded by the following grant: BFU 2006-05055/BFI.
- 2005). Motility patterns and distribution of interstitial cells of Cajal and nitrergic neurons in the proximal, mid- and distal-colon of the rat. Neurogastroenterol Motil 17: 133–147. , , , (
- 2008). Guide to receptors and channels (GRAC), 3rd edition. Br J Pharmacol 153 (Suppl. 2): S1–S209. , , (
- 2003). The P2Y(1) receptor as a target for new antithrombotic drugs: a review of the P2Y(1) antagonist MRS-2179. Cardiovasc Drug Rev 21: 67–76. , (
- 2001). Inhibition of platelet function by administration of MRS2179, a P2Y1 receptor antagonist. Eur J Pharmacol 412: 213–221. , , , , , et al. (
- 2008). Purinergic mechanisms in the control of gastrointestinal motility. Purinergic Signal 4: 197–212. (
- 1998). Competitive and selective antagonism of P2Y1 receptors by N6-methyl 2′-deoxyadenosine 3′,5′-bisphosphate. Br J Pharmacol 124: 1–3. , , , , (
- 2002). 2-Chloro N(6)-methyl-(N)-methanocarba-2′-deoxyadenosine-3′,5′-bisphosphate is a selective high affinity P2Y(1) receptor antagonist. Br J Pharmacol 135: 2004–2010. , , , , (
- 2007). Purine and pyrimidine receptors. Cell Mol Life Sci 64: 1471–1483. (
- 2008). The journey to establish purinergic signalling in the gut. Neurogastroenterol Motil 20 (Suppl. 1): 8–19. (
- 1970). Evidence that adenosine triphosphate or a related nucleotide is the transmitter substance released by non-adrenergic inhibitory nerves in the gut. Br J Pharmacol 40: 668–688. , , , (
- 1998). Deoxyadenosine bisphosphate derivatives as potent antagonists at P2Y1 receptors. J Med Chem 41: 183–190. , , , , (
- 2004). Antiaggregatory activity in human platelets of potent antagonists of the P2Y 1 receptor. Biochem Pharmacol 68: 1995–2002. , , , , , et al. (
- 1992). Both ATP and the peptide VIP are inhibitory neurotransmitters in guinea-pig ileum circular muscle. J Physiol 447: 119–131. , , (
- 2003). Functional evidence that ATP or a related purine is an inhibitory NANC neurotransmitter in the mouse jejunum: study on the identity of P2X and P2Y purinoceptors involved. Br J Pharmacol 140: 1108–1116. , , , , , (
- 2006). P2Y1 receptors mediate inhibitory purinergic neuromuscular transmission in the human colon. Am J Physiol Gastrointest Liver Physiol 291: G584–G594. , , , (
- 2008a). Purinergic and nitrergic junction potential in the human colon. Am J Physiol Gastrointest Liver Physiol 295: G522–G523. , , , , , (
- 2008b). P2Y1 receptors mediate inhibitory neuromuscular transmission and enteric neuronal activation in small intestine. Neurogastroenterol Motil 20: 159–168. , , , , (
- 2006). The P2Y purinergic receptor expressed by enteric neurones in guinea-pig intestine. Neurogastroenterol Motil 18: 316–323. , , , , , et al. (
- 2002). P2 receptors in the murine gastrointestinal tract. Neuropharmacology 43: 1313–1323. , , , , , et al. (
- 2009). Electrical stimulation of the mucosa evokes slow EPSPs mediated by NK1 tachykinin receptors and by P2Y1 purinoceptors in different myenteric neurons. Am J Physiol Gastrointest Liver Physiol 297: 6179–6186. , (
- 1993). Nitric oxide involvement in the peptide VIP-associated inhibitory junction potential in the guinea-pig ileum. J Physiol 461: 485–499. , (
- 2006). MRS2500 [2-iodo-N6-methyl-(N)-methanocarba-2′-deoxyadenosine-3′,5′-bisphosphate], a potent, selective, and stable antagonist of the platelet P2Y1 receptor with strong antithrombotic activity in mice. J Pharmacol Exp Ther 316: 556–563. , , , , , et al. (
- 2003). Slow excitatory synaptic transmission mediated by P2Y1 receptors in the guinea-pig enteric nervous system. J Physiol 550: 493–504. , , , , , et al. (
- 2002). Nucleotide-mediated relaxation in guinea-pig aorta: selective inhibition by MRS2179. Br J Pharmacol 135: 537–545. , (
- 1993). Enteric inhibitory neural regulation of human colonic circular muscle: role of nitric oxide. Gastroenterology 105: 1009–1016. , , , , (
- 2001). Acyclic and cyclopropyl analogues of adenosine bisphosphate antagonists of the P2Y1 receptor: structure-activity relationships and receptor docking. J Med Chem 44: 3092–3108. , , , , (
- 2002). 2-Chloro-N6-methyl-(N)-methanocarba-2′-deoxyadenosine-3′,5′-bisphosphate is a selective high affinity P2Y1 receptor antagonist: commentary on Boyer et al. Br J Pharmacol 135: 1839–1840. (
- 2008). Involvement of P2Y1 and P2Y11 purinoceptors in parasympathetic inhibition of colonic smooth muscle. J Pharmacol Exp Ther 324: 1055–1063. , (
- 1992). Effects of a nitric oxide synthase inhibitor on non-cholinergic junction potentials in the circular muscle of the guinea pig ileum. J Auton Nerv Syst 41: 187–196. , , , (
- 2008). Functional evidence for purinergic inhibitory neuromuscular transmission in the mouse internal anal sphincter. Am J Physiol Gastrointest Liver Physiol 294: G1041–G1051. , , , , (
- 2004). ATP participates in three excitatory postsynaptic potentials in the submucous plexus of the guinea pig ileum. J Physiol 556: 571–584. , , (
- 1999). Neural modulation of the cyclic electrical and mechanical activity in the rat colonic circular muscle: putative role of ATP and NO. Br J Pharmacol 126: 883–892. , , (
- 1998). Receptors for purines and pyrimidines. Pharmacol Rev 50: 413–492. , (
- 2002). Adenine nucleotide analogues locked in a Northern methanocarba conformation: enhanced stability and potency as P2Y(1) receptor agonists. J Med Chem 45: 2090–2100. , , , , , et al. (
- 2007). Inhibitory purinergic P2 receptor characterisation in rat distal colon. Neuropharmacology 53: 257–271. , , , (
- 2006). Pharmacological profiles of cloned mammalian P2Y-receptor subtypes. Pharmacol Ther 110: 415–432. (
- 2007). Inhibitory neuromuscular transmission mediated by the P2Y1 purinergic receptor in guinea pig small intestine. Am J Physiol Gastrointest Liver Physiol 292: G1483–G1489. , , , , , et al. (
- 2006). The enteric purinergic P2Y1 receptor. Curr Opin Pharmacol 6: 564–570. (
- 2007). Inhibitory purinergic transmission in mouse caecum: role for P2Y1 receptors as prejunctional modulators of ATP release. Neuroscience 150: 658–664. , , (